Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lonafarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 20/20 | 1.00 |
| ▸ | FNTB known ✓ | P49356 | 20/20 | 1.00 |
| ▸ | HRAS | P01112 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonafarnib SCHEMBL21630385 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL19032 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL29517258 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13578722 | 0.93 | FNTA (0.88) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL6956843 | 0.93 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL17547678 | 0.92 | FNTA (0.86) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL31510741 | 0.92 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL12022170 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13524750 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL14148187 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303564-A1 | METHOD FOR TREATING A NEURODEGENERATIVE DISORDER | RUSH UNIVERSITY MEDICAL CENTER | 2013-11-14 | — | — | US | claimed |
| US-12029819-B2 | Pharmaceutical compositions comprising lonafarnib and ritonavir | EIGER BIOPHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11793793-B2 | Treatment of hepatitis delta virus infection | EIGER BIOPHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793793-B2 | Treatment of hepatitis delta virus infection | EIGER BIOPHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230218530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LONAFARNIB AND RITONAVIR | EIGER INNOTHERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20230046607-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | EIGER INNOTHERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11517532-B2 | Methods of treating hepatitis delta virus infection | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11311519-B2 | Treatment of hepatitis delta virus infection | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3858352-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | Eiger Biopharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070122379-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070122379-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | CANJI, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070014768-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070014768-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-7157079-B2 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157079-B2 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | CANJI, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517532-B2 | Methods of treating hepatitis delta virus infection | LBR, YWHAZ, EBP | FNTA 2476/4885FNTB 508/4885HRAS 351/4885 |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | FNTA 874/4885FNTB 1328/4885HRAS 1182/4885 |
| US-12029819-B2 | Pharmaceutical compositions comprising lonafarnib and ritonavir | LONP1, ACE, DDX39B | FNTA 3098/4885FNTB 3376/4885HRAS 56/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | FNTA 3062/4885FNTB 1584/4885HRAS 78/4885 |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | FNTA 2/4885FNTB 1/4885HRAS 87/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | FNTA 3062/4885FNTB 1584/4885HRAS 78/4885 |
| US-20070122379-A1 | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS | VHL, TP53, BCOR | FNTA 3096/4885FNTB 2790/4885HRAS 4/4885 |
| US-11311519-B2 | Treatment of hepatitis delta virus infection | IFNG, IFNAR1, HBB | FNTA 742/4885FNTB 82/4885HRAS 304/4885 |
| US-20070014768-A1 | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | VHL, TP53, BCOR | FNTA 3096/4885FNTB 2790/4885HRAS 4/4885 |
| US-20230046607-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | IFNG, IFNAR1, HBB | FNTA 742/4885FNTB 82/4885HRAS 304/4885 |
| US-20230218530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LONAFARNIB AND RITONAVIR | LONP1, ACE, DDX39B | FNTA 3098/4885FNTB 3376/4885HRAS 56/4885 |
| US-11793793-B2 | Treatment of hepatitis delta virus infection | IFNG, IFNAR1, HBB | FNTA 742/4885FNTB 82/4885HRAS 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.